CN115998686A - Preparation method of tylosin tartrate soluble powder - Google Patents
Preparation method of tylosin tartrate soluble powder Download PDFInfo
- Publication number
- CN115998686A CN115998686A CN202111235468.5A CN202111235468A CN115998686A CN 115998686 A CN115998686 A CN 115998686A CN 202111235468 A CN202111235468 A CN 202111235468A CN 115998686 A CN115998686 A CN 115998686A
- Authority
- CN
- China
- Prior art keywords
- tylosin tartrate
- preparation
- soluble powder
- tartrate
- tylosin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a preparation method of tylosin tartrate soluble powder. The preparation comprises the following components: 10-20% of tavancomycin tartrate, 2.5-5% of yellow dextrin, 5-10% of disodium ethylenediamine tetraacetate, 5-10% of acidulant and 5-10% of acacia, and the auxiliary material is anhydrous glucose. The method is prepared through the working procedures of liquid preparation, high-speed shearing and spray drying. The preparation prepared by the method has the advantages of high solubility of about 6.5 ten thousand PPM, good solution clarity, good aqueous solution stability and the like.
Description
Technical Field
The invention belongs to the field of veterinary medicines in the field of biological medicine, and in particular relates to a preparation method of tylosin tartrate soluble powder.
Background
The tylosin tartrate is a new generation of macrolide antibiotics, is the antibiotic with the strongest activity of killing mycoplasma at present, and the metabolite of the tylosin tartrate has very strong killing activity on pathogens such as mycoplasma pneumoniae and the like, and can activate macrophages of organisms, so that the number of the macrophages is increased, the phagocytic function is enhanced, the secretion of lysozyme is promoted, and the nonspecific immune function of the organisms is enhanced.
The tylosin tartrate is dissolved in water, and the water solubility of the tylosin tartrate is measured to be about 50000ppm according to the source of the raw materials. In clinical application, because the tylosin tartrate is a raw material obtained through biological fermentation, floccules can appear in a high-concentration aqueous solution of the preparation, and the preparation can be thoroughly dissolved by long-time stirring. The most common mode of administration in large-scale farms is administration through drinking water, and the floccules of the preparation can block the waterline and the drinking water head, so that the clinical application of the product is greatly limited.
Therefore, we consider to find a method which has good water solubility and can eliminate floc of the teicoplanin soluble powder in the aqueous solution so as to solve the problem that the water path is easy to block in clinical use.
In the research process, we find that adding yellow dextrin with a certain proportion can increase the water solubility of the tylosin tartrate, the water solution of the tylosin tartrate at the acidic pH is more stable, and adding disodium edetate enables the tylosin tartrate to form chelate, so that floccules formed in water can be completely eliminated. The acacia can play a role in thickening to ensure the uniformity of materials in the processing process and the uniformity of aqueous solutions in the clinical use process, and can play a certain role in protecting in the spray drying process.
Disclosure of Invention
The invention adopts the following technical scheme:
the invention aims to provide a preparation method of tylosin tartrate soluble powder. The composite material comprises the following components in parts by weight: 10-20% of tavancomycin tartrate, 2.5-5% of yellow dextrin, 5-10% of disodium ethylenediamine tetraacetate, 5-10% of acidulant, 5-10% of acacia and anhydrous glucose.
The invention provides a preparation method of tylosin tartrate soluble powder, wherein the acidulant is aspartic acid or glutamic acid.
The ratio of the telavancin tartrate to the yellow dextrin is 1:0.25
The ratio of the telavancin tartrate to the disodium ethylenediamine tetraacetate is 1:0.5
The ratio of the telavancin tartrate to the acidulant is 1:0.5
The ratio of the telavancin tartrate to the Arabic gum is 1:0.5
The preparation method of the tylosin tartrate soluble powder comprises the following steps:
step 1: mixing telavancin tartrate, yellow dextrin and EDTA-2NA, dissolving in water, adding acidulant, and stirring.
Step 2: adding water into acacia to prepare a mucilage solution for standby.
Step 3: and (3) mixing the solutions obtained in the step (1) and the step (2), uniformly stirring, and adding a proper amount of anhydrous glucose to form uniform suspension liquid.
Step 4: and (3) placing the suspension liquid in the step (3) into a high-speed shearing emulsifying pot, and shearing for later use.
Step 5: and (5) spray drying the liquid obtained in the step (4), and subpackaging with aluminum foil bags.
The preparation method of the tylosin tartrate soluble powder provided by the invention has the advantages that the prepared tylosin tartrate soluble powder has good water solubility and can not generate floccules. The amino acid can be used as an acidulant and can play a role in buffering in aqueous solution so that the aqueous solution of the preparation is more stable, and the amino acid can also provide necessary nutrients for animals.
Detailed Description
The advantages and features of the present invention will become more apparent from the following description of the embodiments. These examples are merely exemplary and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Example 1: the method for preparing the tylosin tartrate soluble powder
Step 1: taking 20g of telavancin tartrate (calculated by a dry product), 5g of yellow dextrin and 10g of EDTA-2NA, primarily mixing, adding 200ml of water to dissolve, adding 10g of aspartic acid after dissolving, and uniformly stirring to completely dissolve for standby.
Step 2: 10g of Arabic gum is taken, 30ml of water is added to stir the mucilage solution uniformly for standby.
Step 3: mixing the solutions obtained in the step 1 and the step 2, uniformly stirring, adding 36g of anhydrous glucose, and stirring to form uniform suspension liquid.
Step 4: and (3) placing the suspension liquid obtained in the step (3) into a high-speed shearing emulsifying pot, and shearing for 20 minutes at the temperature of 45 ℃.
Step 5: and (3) spray drying the liquid obtained in the step (4), setting the drying stability at 170 ℃, setting the pressure of a high-pressure pump at 16-20mpa, collecting the powder after spray drying, and sub-packaging and sealing the powder by using an aluminum foil bag to obtain the sample 1.
Example 2: tewanocin tartrate soluble powder prepared by common method
Taking 20g (calculated as a dry product) of telavancin tartrate, adding anhydrous glucose to 100g, crushing, uniformly mixing, and then filling in an aluminum foil bag to obtain a sample 2.
Example 3: teleomycin tartrate soluble powder prepared by adding common acidulant
Taking 20g of telavancin tartrate (calculated as a dry product) and 10g of tartaric acid, adding anhydrous glucose to 100g, crushing and uniformly mixing, and then filling the mixture in an aluminum foil bag to obtain a sample 3.
Example 4: teleomycin tartrate soluble powder prepared by adding common acidulant and disodium ethylenediamine tetraacetate
Taking 20g of telavancin tartrate (calculated as a dry product) and 10g of tartaric acid, adding 10g of EDTA-2NA into 100g of anhydrous glucose, crushing and uniformly mixing, and then filling the mixture into an aluminum foil bag to obtain the sample 4.
Example 5:
20g of each was taken and 100ml of water was added thereto, followed by stirring for 1 minute to observe the water solubility.
The experiment shows that the water solubility of the tylosin tartrate soluble powder prepared by the method is better than that of the tylosin tartrate soluble powder prepared by the common method, the aqueous solution of the tylosin tartrate soluble powder is more stable when the aspartic acid is used as an acidulant in terms of stability, the phenomenon of product floccules in the aqueous solution can be completely eliminated when the disodium edetate is used, and no preparation of the disodium edetate needs to be placed for a long time to eliminate the floccules.
Example 6:
taking 20g of the tavancomycin tartrate raw material and 5g of yellow dextrin, and uniformly mixing for later use. As sample 1.
Taking 20g of the tavancomycin tartrate raw material for standby. As sample 2.
Slowly adding the above two materials into 100ml water, stirring while adding until insoluble substances appear, and recording the addition amount.
Through experiments, the solubility and the water solubility of the tylosin tartrate added with the yellow dextrin are superior to those of the common tylosin tartrate.
Claims (6)
1. A method for preparing a tylosin tartrate soluble powder, wherein the veterinary formulation comprises: 10-20% of tavancomycin tartrate, 2.5-5% of yellow dextrin, 5-10% of disodium ethylenediamine tetraacetate, 5-10% of acidulant and 5-10% of acacia.
2. The method for preparing the tylosin tartrate soluble powder according to claim 1, wherein the acidulant is aspartic acid, and the use ratio of the acidulant to the tylosin tartrate is 0.5:1.
3. The method for preparing the tylosin tartrate soluble powder according to claim 1, wherein the use ratio of the tylosin tartrate to the yellow dextrin is 1:0.25.
4. The method for preparing the tylosin tartrate soluble powder according to claim 1, wherein the use ratio of the tylosin tartrate to the disodium edetate is 1:1.
5. The method for preparing the tylosin tartrate soluble powder according to claim 1, wherein the use ratio of the tylosin tartrate to the acacia is 1:1.
6. The preparation method of the tylosin tartrate soluble powder comprises the following main process steps and process parameters:
the preparation uses a high-speed shearing emulsification process, wherein the temperature of the intermediate liquid medicine is not more than 45 ℃ in the preparation process, and the shearing time is 20 minutes.
The preparation is prepared by spray drying process, wherein the drying stability is 170deg.C, and the high pressure pump pressure is 16-20mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111235468.5A CN115998686A (en) | 2021-10-22 | 2021-10-22 | Preparation method of tylosin tartrate soluble powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111235468.5A CN115998686A (en) | 2021-10-22 | 2021-10-22 | Preparation method of tylosin tartrate soluble powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115998686A true CN115998686A (en) | 2023-04-25 |
Family
ID=86027238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111235468.5A Pending CN115998686A (en) | 2021-10-22 | 2021-10-22 | Preparation method of tylosin tartrate soluble powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115998686A (en) |
-
2021
- 2021-10-22 CN CN202111235468.5A patent/CN115998686A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101869188B (en) | Preparation method of nosiheptide premix | |
| CN106995502B (en) | Bifunctional group modified chitosan derivative and preparation method thereof | |
| JP2023027088A (en) | Process for making pullulan | |
| CN102133199A (en) | Doxofylline lyophilized preparation for injection and preparation method thereof | |
| CN104857517A (en) | Enzalutamide soft capsule and preparation method thereof | |
| CN104721155A (en) | Temozolomide lyophilized powder preparation and preparation method thereof | |
| CN113603797B (en) | Amino nano-cellulose and preparation method thereof | |
| EP3505156B1 (en) | Manufacturing process of cyclosporin eye gel | |
| CN108410928B (en) | Preparation method and application of high-concentration small-molecule hyaluronic acid | |
| CN115998686A (en) | Preparation method of tylosin tartrate soluble powder | |
| CN110464846A (en) | A kind of Meloxicam composition, preparation and the preparation method and application thereof | |
| CN102617643B (en) | Riboflavin sodium phosphate compound | |
| CN106467561A (en) | A kind of sharp separation, the method for purification Radix Ginseng arginine glycoside | |
| CN109646410A (en) | Stable azacitidine lyophilized preparation and preparation method thereof | |
| CN107137360A (en) | A kind of injection azacitidine lyophilized formulations | |
| CN105622778A (en) | Preparation method of water-soluble chitosan | |
| CN110279658A (en) | A kind of oxytocin injection and preparation method thereof | |
| CN102429828B (en) | Coenzyme Q10 microcapsule and preparation method and application thereof | |
| CN101822822A (en) | Drug composition of pramlintide and preparation method thereof | |
| CN108078931A (en) | A kind of bendamustine hydrochloride freeze-dried powder pin and preparation method thereof | |
| CN108743548B (en) | Cefprozil granules and preparation method thereof | |
| JPS6363388A (en) | Production of low molecular weight chitosan | |
| CN107595769A (en) | A kind of preparation method of Fondaparinux sodium injecta composition | |
| CN113952308A (en) | Albendazole granules and preparation method thereof | |
| CN109431996B (en) | Minoxidil-containing external preparation composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |